Attached files

file filename
EX-10.32 - EX-10.32 - BIODELIVERY SCIENCES INTERNATIONAL INCbdsi1032pleshaamendment.htm
EX-32.2 - EX-32.2 - BIODELIVERY SCIENCES INTERNATIONAL INCbdsi-20201231x10qex322.htm
EX-32.1 - EX-32.1 - BIODELIVERY SCIENCES INTERNATIONAL INCbdsi-20201231x10qex321.htm
EX-31.2 - EX-31.2 - BIODELIVERY SCIENCES INTERNATIONAL INCbdsi-20201231x10kex312.htm
EX-31.1 - EX-31.1 - BIODELIVERY SCIENCES INTERNATIONAL INCbdsi-20201231x10qex311.htm
EX-23.1 - EX-23.1 - BIODELIVERY SCIENCES INTERNATIONAL INCa2020exhibit231.htm
EX-21.1 - EX-21.1 - BIODELIVERY SCIENCES INTERNATIONAL INCa2020exhibit211.htm
EX-10.33 - EX-10.33 - BIODELIVERY SCIENCES INTERNATIONAL INCbdsi1033baileyofferlette.htm
EX-10.31 - EX-10.31 - BIODELIVERY SCIENCES INTERNATIONAL INCbdsi1031coelhoamendment.htm
EX-10.30 - EX-10.30 - BIODELIVERY SCIENCES INTERNATIONAL INCbdsi1030vollinsamendment.htm
EX-4.1 - EX-4.1 - BIODELIVERY SCIENCES INTERNATIONAL INCbdsi41securities.htm
10-K - 10-K - BIODELIVERY SCIENCES INTERNATIONAL INCbdsi-20201231.htm
Exhibit 23.2

Consent of Independent Registered Public Accounting Firm


We hereby consent to the incorporation by reference in each of the Registration Statements on Form S-3 (Nos. 333-228292 and 333-232880) and on Form S-8 (Nos. 333-143590, 333-176476, 333-190796, 333-206326, 333-222734, 333-190796, and 333-232879), of our report dated March 12, 2020 included in this Annual Report on Form 10-K of BioDelivery Sciences International, Inc. and subsidiaries (the “Company”), relating to the consolidated balance sheets of the Company as of December 31, 2019, the related consolidated statements of operations, stockholders’ equity (deficit), and cash flows for each of the years in the two-year period ended December 31, 2019, and Schedule II – Valuation and Qualifying Accounts and Reserves for each of the years in the two-year period ended December 31, 2019.


/s/ Cherry Bekaert LLP


Raleigh, North Carolina
March 11, 2021